{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:59:06Z","timestamp":1764403146432},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"DOI":"10.7759\/cureus.23452","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T22:30:07Z","timestamp":1648161007000},"source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Sharina C","family":"Macapagal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javaria","family":"Abdul Jabbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Caroline","family":"Fjorden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene Tresa","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramanpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihan A","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis","volume":"52","author":"Piris MA","year":"2020","unstructured":"Piris MA, Medeiros LJ, Chang KC. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology. 2020, 52:154-65. 10.1016\/j.pathol.2019.09.005","journal-title":"Pathology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v13.i6.503","article-title":"Immunotherapy in the treatment of lymphoma","volume":"13","author":"Popovic LS","year":"2021","unstructured":"Popovic LS, Matovina-Brko G, Popovic M, et al.. Immunotherapy in the treatment of lymphoma. World J Stem Cells. 2021, 13:503-20. 10.4252\/wjsc.v13.i6.503","journal-title":"World J Stem Cells"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1488254","article-title":"18F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors","volume":"60","author":"Castello A","year":"2019","unstructured":"Castello A, Grizzi F, Qehajaj D, Rahal D, Lutman F, Lopci E. 18F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leuk Lymphoma. 2019, 60:367-75. 10.1080\/10428194.2018.1488254","journal-title":"Leuk Lymphoma"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz R","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F, et al.. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019, 30:612-20. 10.1093\/annonc\/mdz009","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14740\/jh596","article-title":"Prolonged remission by pembrolizumab and brentuximab-vedotin combination therapy in heavily-pretreated relapsed\/refractory Hodgkin's lymphoma","volume":"9","author":"Yu TY","year":"2020","unstructured":"Yu TY, Dai MS. Prolonged remission by pembrolizumab and brentuximab-vedotin combination therapy in heavily-pretreated relapsed\/refractory Hodgkin's lymphoma. J Hematol. 2020, 9:30-2. 10.14740\/jh596","journal-title":"J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.08.014","article-title":"Challenges and perspectives in the immunotherapy of Hodgkin lymphoma","volume":"85","author":"Michot JM","year":"2017","unstructured":"Michot JM, Lazarovici J, Ghez D, et al.. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. Eur J Cancer. 2017, 85:67-77. 10.1016\/j.ejca.2017.08.014","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081071","article-title":"Immunotherapy in Hodgkin lymphoma: present status and future strategies","volume":"11","author":"Vassilakopoulos TP","year":"2019","unstructured":"Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV, Arapaki M, Tzoras E, Angelopoulou MK, Konstantopoulos K. Immunotherapy in Hodgkin lymphoma: present status and future strategies. Cancers (Basel). 2019, 11:1071. 10.3390\/cancers11081071","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2019.05.005","article-title":"A targeted salvage therapy with brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation","volume":"61","author":"Ta\u00e7y\u0131ld\u0131z N","year":"2019","unstructured":"Ta\u00e7y\u0131ld\u0131z N, Tany\u0131ld\u0131z HG, \u00dcnal E, et al.. A targeted salvage therapy with brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. Turk J Pediatr. 2019, 61:671-6. 10.24953\/turkjped.2019.05.005","journal-title":"Turk J Pediatr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00771","article-title":"Checkpoint inhibition therapy in transplant-ineligible relapsed or refractory classic Hodgkin lymphoma","volume":"17","author":"Al-Hadidi SA","year":"2021","unstructured":"Al-Hadidi SA, Lee HJ. Checkpoint inhibition therapy in transplant-ineligible relapsed or refractory classic Hodgkin lymphoma. JCO Oncol Pract. 2021, 17:64-71. 10.1200\/OP.20.00771","journal-title":"JCO Oncol Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes A","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, et al.. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012, 30:2183-9. 10.1200\/JCO.2011.38.0410","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-03039-w","article-title":"Safety profile of brentuximab vedotin in Japanese patients with relapsed\/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study","volume":"113","author":"Izutsu K","year":"2021","unstructured":"Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M. Safety profile of brentuximab vedotin in Japanese patients with relapsed\/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study. Int J Hematol. 2021, 113:404-12. 10.1007\/s12185-020-03039-w","journal-title":"Int J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen R","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, et al.. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016, 128:1562-6. 10.1182\/blood-2016-02-699850","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03899-1","article-title":"Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience","volume":"99","author":"\u00d6zbalak M","year":"2020","unstructured":"\u00d6zbalak M, Saliho\u011flu A, Soysal T, et al.. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Ann Hematol. 2020, 99:301-7. 10.1007\/s00277-019-03899-1","journal-title":"Ann Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0454-z","article-title":"Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma","volume":"54","author":"Abuelgasim KA","year":"2019","unstructured":"Abuelgasim KA, Alzahrani M, Alsharhan Y, et al.. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2019, 54:1168-72. 10.1038\/s41409-019-0454-z","journal-title":"Bone Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13400","article-title":"Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study","volume":"104","author":"Iannitto E","year":"2020","unstructured":"Iannitto E, Romano A, Scalzulli PR, et al.. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. Eur J Haematol. 2020, 104:581-7. 10.1111\/ejh.13400","journal-title":"Eur J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16499","article-title":"Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma","volume":"189","author":"LaCasce AS","year":"2020","unstructured":"LaCasce AS, Bociek RG, Sawas A, et al.. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Br J Haematol. 2020, 189:e86-90. 10.1111\/bjh.16499","journal-title":"Br J Haematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3007-9","article-title":"Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma","volume":"96","author":"Hwang YY","year":"2017","unstructured":"Hwang YY, Khong PL, Kwong YL. Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol. 2017, 96:1219-20. 10.1007\/s00277-017-3007-9","journal-title":"Ann Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand P","year":"2018","unstructured":"Armand P, Engert A, Younes A, et al.. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018, 36:1428-39. 10.1200\/JCO.2017.76.0793","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa117","article-title":"Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma","volume":"50","author":"Maruyama D","year":"2020","unstructured":"Maruyama D, Terui Y, Yamamoto K, et al.. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Jpn J Clin Oncol. 2020, 50:1265-73. 10.1093\/jjco\/hyaa117","journal-title":"Jpn J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000401","article-title":"A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory Hodgkin lymphoma after nivolumab monotherapy failure","volume":"4","author":"Lepik KV","year":"2020","unstructured":"Lepik KV, Mikhailova NB, Kondakova EV, et al.. A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory Hodgkin lymphoma after nivolumab monotherapy failure. Hemasphere. 2020, 4:e401. 10.1097\/HS9.0000000000000401","journal-title":"Hemasphere"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211038181","article-title":"Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review","volume":"12","author":"Romero S","year":"2021","unstructured":"Romero S, Balaguer-Rosell\u00f3 A, Montoro J, et al.. Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review. Ther Adv Hematol. 2021, 12:20406207211038181. 10.1177\/20406207211038181","journal-title":"Ther Adv Hematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera AF","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, et al.. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018, 131:1183-94. 10.1182\/blood-2017-10-811224","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani RH","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, et al.. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021, 138:427-38. 10.1182\/blood.2020009178","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach CS","year":"2020","unstructured":"Diefenbach CS, Hong F, Ambinder RF, et al.. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial. Lancet Haematol. 2020, 7:e660-70. 10.1016\/S2352-3026(20)30221-0","journal-title":"Lancet Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/87701-efficacy-of-brentuximab-vedotin-and-nivolumab-in-refractory-or-relapsed-hodgkin-lymphoma-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:09Z","timestamp":1707507789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/87701-efficacy-of-brentuximab-vedotin-and-nivolumab-in-refractory-or-relapsed-hodgkin-lymphoma-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.23452","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}